Pelish Henry E.

Pelish Henry E., Chief Scientific Officer at Nuvalent (NUVL), has been an active seller of company stock over the past year, with no open-market purchases recorded. Across 66 total Form 4 transactions, his sales total approximately $8.02 million, all in NUVL shares. The most recent activity, dated July 15, 2026, shows a cluster of "D" transactions (sales back to the issuer) valued at zero, alongside a single "A" grant and a "U" transaction worth $2.78 million — the latter likely representing a derivative conversion or similar non-market event. The absence of any "P" purchases in the filing history underscores a consistent divestment posture. The selling pattern is concentrated in quarterly windows, with notable activity in March, April, and July 2026. On March 12, Pelish executed three sales totaling roughly $2.94 million, paired with option exercises ("M") valued at about $386,000 — a classic exercise-and-sell structure. Additional sales on March 13 brought in $505,000, while April 9 saw two sales worth $323,000 alongside a small option exercise. The most recent open-market sale occurred July 9, netting $261,363. These transactions are routine for an executive with equity compensation, but the scale — particularly the $2.36 million single-day sale on March 12 — indicates a deliberate reduction of his NUVL position over time. Notably, the July 15 "D" transactions carry zero dollar values, suggesting non-cash dispositions such as share surrenders or transfers, while the "U" entry of $2.78 million may reflect a conversion event. Overall, Pelish’s filings reveal a clear seller bias — no buys, no acquisitions outside of compensation grants, and a steady stream of sales that aligns with standard insider liquidity management rather than any clustered or opportunistic timing. Investors tracking insider sentiment at Nuvalent would see this as a consistent, if not aggressive, reduction in exposure by a senior officer.